Log In
Print
BCIQ
Print
Print this Print this
 

Aldurazyme, laronidase

  Manage Alerts
Collapse Summary General Information
Company BioMarin Pharmaceutical Inc.
DescriptionRecombinant alpha-L-iduronidase
Molecular Target Lymphotoxin beta receptor (LTBR)
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentMarketed
Standard IndicationMucopolysaccharidosis
Indication DetailsTreat mucopolysaccharidosis I (MPS I, Hurler syndrome); Treat non-neurological manifestations of mucopolysaccharidosis I (MPS I)
Regulatory Designation

Switzerland - Orphan Drug (Treat mucopolysaccharidosis I (MPS I, Hurler syndrome))

Partner

Sanofi


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today